Cancer-Associated Thrombotic Microangiopathy: Literature Review and Report of Five Cases

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Jul 27

PMID 39063619

Authors

L Posado-Dominguez

A-J Chamorro

E Del Barco-Morillo

M Martin-Galache

D Bueno-Sacristan

E Fonseca-Sanchez

A Olivares-Hernandez

Affiliations

Soon will be listed here.

Abstract

Thrombotic microangiopathy (TMA) is an anatomopathological lesion mediated by endothelial dysfunction and characterized by the creation of microthrombi in small vessels. In patients with cancer, it may be due to toxicity secondary to chemotherapy, tumor embolization, or hematopoietic progenitor transplantation. Cancer-associated TMA is an underestimated entity that generally appears in the final stages of the disease, although it may also be the initial manifestation of an underlying cancer. Support treatment is necessary in all cases and, depending on the cause, different targeted therapies may be used. The prognosis is very poor. In this article we present a comprehensive review of the existing literature on the physiological mechanisms of cancer-associated TMA. Afterwards, five clinical cases will be presented of patients who developed TMA and were diagnosed in our Department in 2023. We present a discussion of the different causes that triggered the condition, the possible reasons behind the underestimation of this pathology, and the measures that may be adopted.

References

Mitsui Y, Yagi M, Muraki S, Matsuura T, Bando Y, Fujimoto S . Pulmonary Tumor Thrombotic Microangiopathy Due to Gastric Cancer Diagnosed Antemortem by a Cytological Examination of Aspirated Pulmonary Artery Blood. Intern Med. 2021; 61(10):1491-1495. PMC: 9177363. DOI: 10.2169/internalmedicine.8313-21. View

Weitz I . Thrombotic Microangiopathy in Cancer. Semin Thromb Hemost. 2019; 45(4):348-353. DOI: 10.1055/s-0039-1687893. View

van der Poll T, Jansen P, Van Zee K, Welborn 3rd M, de Jong I, Hack C . Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood. 1996; 88(3):922-7. View

Montes-Worboys A, Rodriguez-Portal J, Arellano-Orden E, Digon-Pereiras J, Rodriguez-Panadero F . Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis. Eur Respir J. 2009; 35(1):160-6. DOI: 10.1183/09031936.00146808. View

Lopes A, Maeda N, Almeida A, Jaeger R, Ebaid M, Chamone D . Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension. Angiology. 1993; 44(9):701-6. DOI: 10.1177/000331979304400905. View

Garcia J, Hurwitz H, Sandler A, Miles D, Coleman R, Deurloo R . Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020; 86:102017. DOI: 10.1016/j.ctrv.2020.102017. View

Guo W, Hou P, Tan W, Lei Y, Wu X, Huang H . [A case of metastatic breast cancer complicated by pulmonary tumor thrombotic microangiopathy]. Zhonghua Jie He He Hu Xi Za Zhi. 2023; 46(10):1014-1018. DOI: 10.3760/cma.j.cn112147-20230521-00253. View

Padilha W, Cesar B, Pacheco S, De Sousa A, Ledesma F, Malheiros D . Bevacizumab-Associated Thrombotic Microangiopathy Treated with Eculizumab: A Case Report. Am J Case Rep. 2023; 24:e940906. PMC: 10474846. DOI: 10.12659/AJCR.940906. View

Uruga H, Fujii T, Kurosaki A, Hanada S, Takaya H, Miyamoto A . Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med. 2013; 52(12):1317-23. DOI: 10.2169/internalmedicine.52.9472. View

10.

Krisinger M, Goebeler V, Lu Z, Meixner S, Myles T, Pryzdial E . Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood. 2012; 120(8):1717-25. DOI: 10.1182/blood-2012-02-412080. View

11.

Mingot Castellano M, Izquierdo C, Gonzalez A, Viejo Llorente A, Ferreiras D, Sebastian E . Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura. Med Clin (Barc). 2021; 158(12):630.e1-630.e14. DOI: 10.1016/j.medcli.2021.03.040. View

12.

Sutter T, Fehr T, Venzin R . [CME: Diagnostic Approach and Management of Thrombotic Microangiopathy]. Praxis (Bern 1994). 2022; 111(14):771-777. DOI: 10.1024/1661-8157/a003927. View

13.

Minamikawa K, Wada H, Ohiwa M, Kaneko T, Tsukada T, Kageyama S . [Plasma interleukin-6 in patients with disseminated intravascular coagulation]. Rinsho Ketsueki. 1992; 33(12):1797-801. View

14.

Michael M, Bagga A, Sartain S, Smith R . Haemolytic uraemic syndrome. Lancet. 2022; 400(10364):1722-1740. DOI: 10.1016/S0140-6736(22)01202-8. View

15.

Ho V, Cutler C, Carter S, Martin P, Adams R, Horowitz M . Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11(8):571-5. DOI: 10.1016/j.bbmt.2005.06.001. View

16.

Nakano Y, Kumagai J, Nagahama K, Fujisawa H . A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings. BMJ Case Rep. 2021; 14(3). PMC: 7929848. DOI: 10.1136/bcr-2020-239603. View

17.

Key N, Khorana A, Kuderer N, Bohlke K, Lee A, Arcelus J . Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019; 38(5):496-520. DOI: 10.1200/JCO.19.01461. View

18.

Kaiser R, Leunig A, Pekayvaz K, Popp O, Joppich M, Polewka V . Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19. JCI Insight. 2021; 6(18). PMC: 8492337. DOI: 10.1172/jci.insight.150862. View

19.

FERNANDO VALDES E . [New paraneoplastic syndrome: peripheral obliterating microangiopathy associated with recurrent phlebothrombosis and metastatic carcinoma]. Rev Clin Esp. 1969; 113(4):349-52. View

20.

Motwani S, Kaur S, Kitchlu A . Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies. Semin Nephrol. 2023; 42(6):151341. DOI: 10.1016/j.semnephrol.2023.151341. View